Randomized, double-blind, placebo-controlled, multicenter phase ii study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer

Martin J. Edelman, Ming T. Tan, Mary J. Fidler, Rachel E. Sanborn, Greg Otterson, Lecia V. Sequist, Tracey L. Evans, Bryan J. Schneider, Roger Keresztes, John S. Rogers, Jorge Antunez De Mayolo, Josephine Feliciano, Yang Yang, Michelle Medeiros, Sara L. Zaknoen

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Randomized, double-blind, placebo-controlled, multicenter phase ii study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences